3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial

BACKGROUND: 6 months of oxaliplatin-containing chemotherapy is usually given as adjuvant treatment for stage 3 colorectal cancer. We investigated whether 3 months of oxaliplatin-containing chemotherapy would be non-inferior to the usual 6 months of treatment. METHODS: The SCOT study was an internati...

Descripción completa

Detalles Bibliográficos
Autores principales: Iveson, Timothy J, Kerr, Rachel S, Saunders, Mark P, Cassidy, Jim, Hollander, Niels Henrik, Tabernero, Josep, Haydon, Andrew, Glimelius, Bengt, Harkin, Andrea, Allan, Karen, McQueen, John, Scudder, Claire, Boyd, Kathleen Anne, Briggs, Andrew, Waterston, Ashita, Medley, Louise, Wilson, Charles, Ellis, Richard, Essapen, Sharadah, Dhadda, Amandeep S, Harrison, Mark, Falk, Stephen, Raouf, Sherif, Rees, Charlotte, Olesen, Rene K, Propper, David, Bridgewater, John, Azzabi, Ashraf, Farrugia, David, Webb, Andrew, Cunningham, David, Hickish, Tamas, Weaver, Andrew, Gollins, Simon, Wasan, Harpreet S, Paul, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lancet Pub. Group 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5883334/
https://www.ncbi.nlm.nih.gov/pubmed/29611518
http://dx.doi.org/10.1016/S1470-2045(18)30093-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5883334/
https://www.ncbi.nlm.nih.gov/pubmed/29611518
http://dx.doi.org/10.1016/S1470-2045(18)30093-7

Ejemplares similares